外资态度来看，本期较上一季度新披露的外资机构有 1 家 ，即香港中央结算有限公司。 公募基金方面，本期较上一期持股增加的公募基金共计1个，即国泰大健康股票A，持股增加占比小幅 上涨。本期较上一季度持股减少的公募基金共计2个，包括南方中证1000ETF、国泰医药健康股票A，持 股减少占比小幅下跌。本期较上一季未再披露的公募基金共计105个，主要包括华夏中证1000ETF、广 发医疗保健股票A、广发中证1000ETF、博时医疗保健混合A、易方达增强回报债券A等。 2025年10月29日，老百姓(603883.SH)发布2025年第三季报。截至2025年10月28日，共有7个机构投资者 披露持有老百姓A股股份，合计持股量达3.70亿股，占老百姓总股本的48.73%。其中，机构投资者包括 老百姓医药集团有限公司、泽星投资有限公司、香港中央结算有限公司、林芝腾讯科技有限公司、招商 银行股份有限公司-南方中证1000交易型开放式指数证券投资基金、中国建设银行股份有限公司-国泰医 药健康股票型证券投资基金、国泰大健康股票A，机构投资者合计持股比例达48.73%。相较于上一季 度，机构持股比例合计下跌了3.63个百分点。 ...

公募基金方面，本期较上一期持股增加的公募基金共计4个，包括汇添富创新医药混合A、广发医疗保 健股票A、富国精准医疗灵活配置混合A、汇添富医疗服务灵活配置混合A，持股增加占比达1.45%。本 期较上一季度持股减少的公募基金共计1个，即中欧医疗健康混合A，持股减少占比达1.66%。本期较上 一季度新披露的公募基金共计1个，即长城医药产业精选混合发起式A。本期较上一季未再披露的公募 基金共计114个，主要包括广发科技创新混合A、中欧医疗创新股票A、工银前沿医疗股票A、兴全合润 混合A、广发医药健康混合A等。 2025年10月25日，昂利康(002940.SZ)发布2025年第三季报。截至2025年10月24日，共有9个机构投资者 披露持有昂利康A股股份，合计持股量达9435.69万股，占昂利康总股本的46.77%。其中，机构投资者 包括嵊州市君泰投资有限公司、浙江昂利康制药股份有限公司-第一期员工持股计划、浙江昂利康制药 股份有限公司-第一期员工持股计划、中国银行股份有限公司-广发医疗保健股票型证券投资基金、中国 工商银行股份有限公司-中欧医疗健康混合型证券投资基金、中国建设银行股份有限公司-富国精准医疗 灵活配置 ...

险资方向，本期较上一季度新披露的险资投资者共计1个，即中国人寿保险股份有限公司-传统-普通保 险产品-005L-CT001沪。本期较上一季未再披露的养老金基金共计1个，即瑞众人寿保险有限责任公司- 自有资金。 2025年10月24日，丽珠集团(000513.SZ)发布2025年第三季报。截至2025年10月23日，共有10个机构投 资者披露持有丽珠集团A股股份，合计持股量达3.02亿股，占丽珠集团总股本的33.44%。其中，前十大 机构投资者包括健康元药业集团股份有限公司、香港中央结算有限公司、广州市保科力贸易公司、深圳 市海滨制药有限公司、国泰基金管理有限公司-社保基金1102组合、中国农业银行股份有限公司-中证 500交易型开放式指数证券投资基金、中国人寿保险股份有限公司-传统-普通保险产品-005L-CT001沪、 中国人寿保险股份有限公司-传统-普通保险产品-005L-CT001沪、中国工商银行股份有限公司-中欧医疗 健康混合型证券投资基金、上海银行股份有限公司-银华中证创新药产业交易型开放式指数证券投资基 金，前十大机构投资者合计持股比例达33.44%。相较于上一季度，前十大机构持股比例合计上涨了0 ...

Group 1 - The core point of the article is that the AI Fund Guangfa Healthcare Stock A (004851) reported a profit of 724 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.2406 yuan, and a net value growth rate of 14.92% during the reporting period [3] - As of September 5, 2025, the fund's unit net value was 2.18 yuan, and the fund manager, Wu Xingwu, has managed six funds, all of which have positive returns over the past year [3] - The fund's scale reached 5.247 billion yuan by the end of the first half of 2025 [32] Group 2 - The fund's performance compared to similar funds shows a three-month net value growth rate of 14.62%, a six-month growth rate of 30.23%, a one-year growth rate of 42.54%, and a three-year growth rate of -0.70% [6] - The fund's weighted price-to-earnings ratio (TTM) is approximately 51.06 times, while the average for similar funds is -135.64 times [11] - The fund's weighted net profit growth rate (TTM) for the first half of 2025 is -0.28%, indicating a slight decline in profitability [18] Group 3 - As of June 30, 2025, the fund had a maximum drawdown of 42.18% over the past three years, ranking 17th among comparable funds [27] - The fund's top ten holdings include companies such as Zai Lab, Kelun Pharmaceutical, and Hengrui Medicine, indicating a focus on innovative drug sectors [40] - The fund's turnover rate for the last six months was approximately 64.38%, which has been consistently below the average of similar funds for five years [38]

Core Insights - The core viewpoint of the article highlights the performance and key holdings of the Guangfa Healthcare Stock A fund, indicating its strong returns and significant asset size since inception [1]. Fund Performance - The latest net value of Guangfa Healthcare Stock A is 2.0925 yuan - The fund has achieved a weekly return of 0.26%, a three-month return of 14.76%, and a year-to-date return of 29.45% [1]. Fund Details - Guangfa Healthcare Stock A was established on August 10, 2017 - As of June 30, 2025, the fund's total assets amount to 5.247 billion yuan [1]. Top Holdings - The top ten stock holdings of the fund include: - Zai Lab Ltd (泽璟制药-U) - Kelun Pharmaceutical (科伦药业) - Baillie Gifford (百利天恒) - New Horizon Health (新诺威) - Heng Rui Medicine (恒瑞医药) - WuXi AppTec (药明康德) - Dong-E E-Jiao (东阿阿胶) - BeiGene Ltd (百济神州-U) - KAILI Medical (开立医疗) - Huatai Medical (惠泰医疗) - The combined proportion of these top ten holdings is 50.56% [1].

Core Insights - The article discusses the performance and holdings of the Guangfa Healthcare Stock A fund, highlighting its recent net value and returns over various time frames [1] Fund Performance - The latest net value of Guangfa Healthcare Stock A is 2.0837 yuan, reflecting a growth of 0.79% - The fund's return over the past month is 1.25%, ranking 994 out of 1025 in its category - Over the last six months, the fund has achieved a return of 25.87%, ranking 145 out of 986 - Year-to-date, the fund has returned 28.91%, with a ranking of 319 out of 976 [1] Fund Holdings - The top ten holdings of Guangfa Healthcare Stock A account for a total of 50.56%, with the following key positions: - Zai Lab Ltd (9.36%) - Kelun Pharmaceutical (8.62%) - Baillie Gifford (7.47%) - XinNuoWei (4.61%) - Hengrui Medicine (4.45%) - WuXi AppTec (4.07%) - Dong-E E-Jiao (3.07%) - BeiGene Ltd (3.07%) - KAILI Medical (3.01%) - Huatai Medical (2.83%) [1] Fund Background - Guangfa Healthcare Stock A was established on August 10, 2017, and as of June 30, 2025, it has a total scale of 5.247 billion yuan - The fund is managed by Wu Xingwu, who has extensive experience in the investment management field [1][2]

Core Insights - The latest net value of GF Healthcare Stock A (004851) is 2.0674 CNY, reflecting a decrease of 1.09% [1] - The fund has shown a one-month return of 0.67%, ranking 443 out of 455 in its category; a six-month return of 27.59%, ranking 63 out of 441; and a year-to-date return of 27.90%, ranking 137 out of 441 [1] Fund Holdings - The top ten holdings of GF Healthcare Stock A account for a total of 50.56%, with the largest positions being: - Zai Lab Ltd (9.36%) - Kelun Pharmaceutical (8.62%) - Baillie Gifford (7.47%) - XinNuoWei (4.61%) - Hansoh Pharmaceutical (4.45%) - WuXi AppTec (4.07%) - Dong-E E-Jiao (3.07%) - BeiGene Ltd (3.07%) - KAILI Medical (3.01%) - Huatai Medical (2.83%) [1] Fund Overview - GF Healthcare Stock A was established on August 10, 2017, and as of June 30, 2025, it has a total scale of 5.247 billion CNY [1] - The fund manager is Wu Xingwu, who has extensive experience in the investment management field [2]

Group 1 - New Nuo Wei (300765.SZ) released its 2025 semi-annual report on August 16, 2025, with 71 institutional investors disclosing holdings of 1.194 billion shares, accounting for 85.00% of the total share capital [1] - The top ten institutional investors hold a combined 81.64% of shares, with a 1.63 percentage point increase compared to the previous quarter [1] Group 2 - In the public fund sector, seven funds increased their holdings, with a total increase of 1.04%, while 26 funds decreased their holdings, with a total decrease of 0.71% [2] - A total of 33 new public funds were disclosed this period, while 32 funds were not disclosed compared to the previous quarter [2] - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.36% [2]

Core Insights - The latest net value of GF Healthcare Stock A (004851) is 2.0249 yuan, reflecting a decline of 1.32% [1] - The fund has shown a one-month return of 6.25%, a six-month return of 26.21%, and a year-to-date return of 25.27%, with respective rankings of 355 out of 656, 77 out of 637, and 148 out of 635 [1] Fund Holdings - The top ten holdings of GF Healthcare Stock A account for a total of 50.56%, with the largest positions being: - Zai Lab Ltd (9.36%) - Kelun Pharmaceutical (8.62%) - Baillie Gifford (7.47%) - XinNuoWei (4.61%) - Hansoh Pharmaceutical (4.45%) - WuXi AppTec (4.07%) - Dong-E E-Jiao (3.07%) - BeiGene Ltd (3.07%) - KAILI Medical (3.01%) - Huatai Medical (2.83%) [1] Fund Background - GF Healthcare Stock A was established on August 10, 2017, and as of June 30, 2025, it has a total scale of 5.247 billion yuan [1] - The fund manager is Wu Xingwu, who has extensive experience in the investment management field [2]

Group 1 - The core point of the article highlights the performance and holdings of the Guangfa Healthcare Stock A fund, which has a recent net value of 2.0748 yuan and a decline of 0.55% [1] - The fund has shown a one-month return of 8.53%, ranking 215 out of 717 in its category, a six-month return of 31.77%, ranking 77 out of 700, and a year-to-date return of 28.36%, ranking 93 out of 697 [1] - The top ten holdings of the fund account for a total of 50.56%, with significant positions in companies such as Zai Lab (9.36%), Kelun Pharmaceutical (8.62%), and Bai Li Tianheng (7.47%) [1] Group 2 - Guangfa Healthcare Stock A fund was established on August 10, 2017, and as of June 30, 2025, it has a total scale of 5.247 billion yuan [1] - The fund manager, Wu Xingwu, has extensive experience in the investment management field, having held various positions in Guangfa Fund Management and other financial institutions [2]